



Suzetrigine for Acute Pain: Effectiveness and Value

Draft Questions for Deliberation and Voting: February 28, 2025 Public Meeting

These questions are intended for the deliberation of the Midwest CEPAC voting body at the public meeting.

Patient Population for all questions: *Adult patients with Acute Pain that is not adequately controlled with non-systemic therapies (e.g. heat therapy, local anesthetic).*

Clinical Evidence

1. For patients with acute pain, is the current evidence adequate to demonstrate that the net health benefit of suzetrigine in addition to non-systemic therapies (e.g. heat therapy, local anesthetic) is greater than that of non-systemic therapies alone?

Yes No

2. For patients with acute pain, is the current evidence adequate to distinguish the net health benefit of suzetrigine from that of oral opioid analgesics (with or without acetaminophen), each in addition to non-systemic therapies?

Yes No

- a. For patients with acute pain, is the current evidence adequate to demonstrate that the net health benefit of suzetrigine is greater than that of oral opioid analgesics (with or without acetaminophen), each in addition to non-systemic therapies?

Yes No

3. For patients with acute pain, is the current evidence adequate to distinguish the net health benefit of suzetrigine from that of oral NSAIDs, each in addition to non-systemic therapies?

Yes No

- a. For patients with acute pain, is the current evidence adequate to demonstrate that the net health benefit of suzetrigine is greater than that of oral NSAIDs, each in addition to non-systemic therapies?

Yes No

Benefits Beyond Health and Special Ethical Priorities

To help inform judgments of overall long-term value for money, please indicate your level of agreement with the following statements:

1=Strongly Disagree; 2=Disagree; 3=Neutral; 4=Agree; 5=Strongly Agree

4. There is substantial unmet need despite currently available treatments.
5. This condition is of substantial relevance for people from a racial/ethnic group that have not been equitably served by the healthcare system.

To help inform judgments of overall long-term value for money, please indicate your level of agreement with the following statements based on the relative effects of suzetrigine versus non-systemic therapies (e.g. heat therapy, local anesthetic), non-opioid analgesics including NSAIDs, acetaminophen, opioid analgesics, and combination with acetaminophen:

1=Strongly Disagree; 2=Disagree; 3=Neutral; 4=Agree; 5=Strongly Agree

6. The treatment is likely to produce substantial improvement in caregivers' quality of life and/or ability to pursue their own education, work, and family life.
7. The treatment offers a substantial opportunity to improve access to effective treatment by means of its mechanism of action or method of delivery.
8. Other: as determined pre-meeting by ICER team based on input from patients, clinical experts, and appraisal committee members

Long-Term Value for Money

9. Given the available evidence on comparative clinical effectiveness and incremental cost effectiveness, and considering benefits beyond health and special ethical priorities, what is the long-term value for money of suzetrigine compared to oral opioid analgesics (with or without acetaminophen) at assumed pricing?*

 - a. High long-term value for money at assumed pricing
 - b. Intermediate long-term value for money at assumed pricing
 - c. Low long-term value for money at assumed pricing

**This vote will only be taken if a price becomes available for suzetrigine.*